Clinical Trial: A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234773) titled 'A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).' on Nov. 13.

Brief Summary: This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis (RA)

Intervention: DRUG: KT501

KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kali Thera...